Vaxcyte EVP Jim Wassil sells $163,862 in company stock
Vaxcyte's EVP Jim Wassil sold 2,715 shares for $163,862 between September 4-9, 2026, at prices ranging $59.155-$61.57. He also surrendered 5,459 shares to cover tax obligations. Vaxcyte's stock is up 82% over the past year, trading at $59.51. The company announced leadership changes and updated its VAX-31 vaccine trial data timeline to October 2026.
How this was made
The 30-second read
Why it matters
The insider sale is a routine disclosure with limited market impact.
Market read
Minor relevance; investors may note the sale but unlikely to adjust positions.
What to watch
Potential tax withholding requirement influencing the surrender of additional shares.
Background
Form 4 filing reveals insider transactions; Vaxcyte recently announced leadership changes and trial timeline updates.
Ticker impact
Executive VP Jim Wassil sold 2,715 shares for $163,862 via a Rule 10b5-1 plan, disclosed in a Form 4 filing.
Minimal short-term price effect
The sale amount is under $1M and follows a pre‑planned trading plan, reducing actionable significance.
Market effects
No immediate sector impact; biotech peers unchanged.
Limited to US biotech investors.
Low global relevance.
Counterpoint
The sale could be routine under a 10b5‑1 plan, not a negative signal.
Key entities
- ExecutiveJim Wassil
Executive Vice President, Chief Scientific Officer and COO of Vaxcyte.
- CompanyVaxcyte, Inc.
Biotech firm developing vaccine candidates.
